Takeda Grants $13.8M to Enhance U.S. Healthy Eating & STEM Education

Takeda Awards $13.8 Million to U.S. Nonprofit Partners to Promote Healthy Eating and Expand STEM Education

April 30, 2025

Annual Grants Deepen Takeda’s Commitment to Improving Health Through Community-Based Programs
Takeda Publishes U.S. Community Impact Report Highlighting Progress toward a More Equitable Health Ecosystem

CAMBRIDGE, Massachusetts, April 30, 2025 – Takeda (TSE:4502/NYSE:TAK) announced today that it has awarded $13.8 million in grants to seven nonprofit partner organizations in the United States that share the company’s commitment to creating better health for people and a brighter future for the world through community-based solutions.

The grant awards are part of the company’s U.S. Corporate Philanthropy Program, which aims to improve access to nutritious food and advance opportunities for engaging educational experiences in science, technology, engineering and mathematics (STEM). Takeda has contributed $67.9 million to these initiatives and other charitable causes since 2021.

“It’s truly an honor for us to support organizations that are driving meaningful change in their local communities,” said Julie Kim, president of Takeda’s U.S. Business Unit and U.S. Country Head. “Their dedication, vision and creativity in providing quality food to those in need and inspiring the next generation of STEM leaders is making a real and lasting impact, and we’re proud to play a role in helping them advance their missions.”

This year’s partner organizations include:

Daily Table Massachusetts – Affordable nonprofit grocery store plans to add two new locations in greater Boston.
Fresh Truck Massachusetts – Provides fresh, high-quality produce to neighborhoods in Boston via mobile markets, online order pick-up sites and community pop-up events.
Food is Medicine Coalition National – Supports nonprofit organizations nationwide in delivering free medically tailored meals and nutrition services.
The Food Group Minnesota – Creating a food ranking framework to promote healthy eating in diverse communities and sharing it with partners across the country.
Learn Fresh National – Launching its engaging, game-based STEM programs across greater Boston and looking to develop and expand its relationships with the area’s professional sports franchises.
STEM Next Opportunity Fund National – Focuses on building math confidence and skills by expanding access to out-of-school STEM programs nationwide.
Young People’s Project National – Grows capacity for math and STEM literacy across the country with its peer-based math literacy programs.

Takeda reviews grant applications for its U.S. Corporate Philanthropy Program twice a year and provides support in the form of grants to local and national organizations of all sizes that align with its philanthropic focus areas. These focus areas are informed by data and by actively listening to leading organizations in the U.S. that understand the areas of greatest need within their communities. This community-centered approach enables Takeda to provide support to address critical needs and make a positive impact in people’s lives.

“Takeda’s support has transformed our capacity to serve students in Boston and across the country,” said Nick Monzi, CEO and co-founder of Learn Fresh. “Since the company’s first grant we have doubled the size of our team, introduced new programs with the Major League Baseball Players Association and Major League Soccer, and reached over 800,000 students nationwide. We appreciate the trust that Takeda has placed in our team to engage educators and students through our robust, mission-aligned partnership.”

In addition to announcing the grant recipients, Takeda today published its 2024 U.S. Community Impact Report, an annual review of the company’s commitment to create more equitable access to high-quality health care, nutritious food and STEM education and to build a diverse workforce and inclusive culture.

About Takeda

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.

Media Contact:

Takeda Media Relations

[email protected]

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

* Annual Grants Deepen Takeda’s Commitment to Improving Health Through Community-Based Programs * Takeda Publishes U.S. Community Impact Report Highlighting Progress toward a More Equitable Health Ecosystem **CAMBRIDGE, Massachusetts, April 30, 2025** – [Takeda](https://www.takeda.com/) (TSE:4502/NYSE:TAK) announced today that it has awarded $13.8 million in grants to seven nonprofit partner organizations in the United States that share the company’s commitment to creating better health for people and a brighter future for the world through community-based solutions. The grant awards are part of the company’s U.S. Corporate Philanthropy Program, which aims to improve access to nutritious food and advance opportunities for engaging educational experiences in science, technology, engineering and mathematics (STEM). Takeda has contributed $67.9 million to these initiatives and other charitable causes since 2021. “It’s truly an honor for us to support organizations that are driving meaningful change in their local communities,” said Julie Kim, president of Takeda’s U.S. Business Unit and U.S. Country Head. “Their dedication, vision and creativity in providing quality food to those in need and inspiring the next generation of STEM leaders is making a real and lasting impact, and we’re proud to play a role in helping them advance their missions.” This year’s partner organizations include: * [Daily Table](http://www.dailytable.org/) **Massachusetts** – Affordable nonprofit grocery store plans to add two new locations in greater Boston. * [Fresh Truck](http://www.freshtruck.org/) **Massachusetts** – Provides fresh, high-quality produce to neighborhoods in Boston via mobile markets, online order pick-up sites and community pop-up events. * [Food is Medicine Coalition](https://fimcoalition.org/) **National** – Supports nonprofit organizations nationwide in delivering free medically tailored meals and nutrition services. * [The Food Group](http://www.thefoodgroupmn.org/) **Minnesota** – Creating a food ranking framework to promote healthy eating in diverse communities and sharing it with partners across the country. * [Learn Fresh](http://www.learnfresh.org/) **National** – Launching its engaging, game-based STEM programs across greater Boston and looking to develop and expand its relationships with the area’s professional sports franchises. * [STEM Next Opportunity Fund](http://stemnext.org/) **National** – Focuses on building math confidence and skills by expanding access to out-of-school STEM programs nationwide. * [Young People’s Project](http://www.typp.org/) **National** – Grows capacity for math and STEM literacy across the country with its peer-based math literacy programs. Takeda reviews grant applications for its U.S. Corporate Philanthropy Program twice a year and provides support in the form of grants to local and national organizations of all sizes that align with its philanthropic focus areas. These focus areas are informed by data and by actively listening to leading organizations in the U.S. that understand the areas of greatest need within their communities. This community-centered approach enables Takeda to provide support to address critical needs and make a positive impact in people’s lives. “Takeda’s support has transformed our capacity to serve students in Boston and across the country,” said Nick Monzi, CEO and co-founder of Learn Fresh. “Since the company’s first grant we have doubled the size of our team, introduced new programs with the Major League Baseball Players Association and Major League Soccer, and reached over 800,000 students nationwide. We appreciate the trust that Takeda has placed in our team to engage educators and students through our robust, mission-aligned partnership.” In addition to announcing the grant recipients, Takeda today published its [2024 U.S. Community Impact Report](/en-us/community-impact-report/), an annual review of the company’s commitment to create more equitable access to high-quality health care, nutritious food and STEM education and to build a diverse workforce and inclusive culture. ## About Takeda Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com. ### Media Contact: Takeda Media Relations [[email protected] ](mailto:[email protected] ) ## Important Notice For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies. ## Forward Looking Statements This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at [www.sec.gov](https://www.sec.gov/). Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.